Anti-MRSA activity of chlorophenyl pyrrolo benzodiazepines compound

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Antibiotic resistance is a critical global health challenge, particularly concerning infections caused by Methicillin-resistant Staphylococcus aureus (MRSA).
• MRSA poses significant treatment difficulties in healthcare settings due to its resistance to multiple antibiotics, including beta-lactams.
• Developing novel antimicrobial agents is crucial to combat the rising threat of antibiotic-resistant pathogens.

Purpose of the Study:

• To synthesize and evaluate a series of novel pyrrolo[1,2-a][1,4]benzodiazepine derivatives for antimicrobial activity.
• To identify potent compounds effective against Gram-positive bacteria, including MRSA.
• To investigate the mechanism of action and potential of these compounds as future antibiotics.

Main Methods:

• Synthesis of highly condensed heterocyclic derivatives of pyrrolo[1,2-a][1,4]benzodiazepines.
• Antimicrobial susceptibility testing against Gram-positive (Staphylococcus aureus, S. epidermidis) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa) bacteria.
• Minimum Inhibitory Concentration (MIC) determination for efficacy assessment.
• Molecular docking studies targeting cell wall biosynthesis proteins of S. aureus.
• Density Functional Theory (DFT) analysis for compound reactivity.
• In vitro biofilm inhibition assays and in silico toxicity assessments.

Main Results:

• The synthesized compounds exhibited significantly stronger antibacterial activity against Gram-positive bacteria compared to Gram-negative bacteria.
• Compound SM-5 demonstrated the highest therapeutic index, with a Minimum Inhibitory Concentration (MIC) of 7.81 µg/mL against Staphylococcus strains.
• Molecular docking revealed strong binding affinities of SM-5 to key bacterial proteins, including PBP2a (-8.3 Kcal/mol), PBP4 (-7.7 Kcal/mol), and lipoteichoic acid synthase (-7.5 Kcal/mol), surpassing methicillin's binding.
• DFT analysis indicated favorable reactivity for compounds SM-5 and SM-6.
• In vitro and in silico studies confirmed substantial biofilm inhibition and acceptable toxicity profiles.

Conclusions:

• The novel pyrrolo[1,2-a][1,4]benzodiazepine derivatives show promising antimicrobial potential, particularly against Gram-positive pathogens.
• Compound SM-5 is identified as a lead candidate due to its potent activity, favorable binding interactions with bacterial targets, and biofilm inhibition capabilities.
• These findings highlight the potential of this chemical class as a source for developing new therapeutic agents to combat antibiotic resistance.